Biotechnology

Novavax Announces Submission of Biologics License Application in South Korea for Approval of NVX-CoV2373

GAITHERSBURG, Md., Nov. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited (SK bioscience), a biotechnology company inSouth Korea, today...

2021-11-15 22:39 2410

RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients

- Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not require hospital care - Top-line results for Part A of the study, designed to evaluate safety and tolerability of RHB-107 and dose sel...

2021-11-15 20:00 2273

Seegene Opens New Subsidiary in Bogotá, Colombia, to Advance Regional COVID-19 Testing

SEOUL, South Korea, Nov. 15, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm specializing in molecular diagnostics (MDx), has announced the opening of an eighth global subsidiary, strategically located in Bogotá,Colombia. The new entity, known as 'Seegene Colombia S.A....

2021-11-15 19:00 1411

Vazyme goes public on Shanghai Stock Exchange today

NANJING, China, Nov. 15, 2021 /PRNewswire/ -- On November 15, 2021, Nanjing Vazyme Biotech Co., Ltd. (Vazyme) went public on the STAR MARKET of the Shanghai Stock Exchange under the stock code 688105. Vazyme goes public on Shanghai Stock Exchan...

2021-11-15 16:28 2690

Labcorp Opens New Integrated Laboratory, Strengthens Bioanalytical Services In Asia-Pacific

SINGAPORE, Nov. 15, 2021 /PRNewswire/ -- Labcorp   (NYSE: LH), a leading global life sciences company, today announced the expansion of its global offerings and its footprint in theAsia-Pacific (APAC) region with the opening of a new, integrated bioanalytical laboratory in...

2021-11-15 16:00 2448

Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021

-ATG-101, a novel PD-L1/4-1BB bispecific antibody, shows potent in vivo anti-tumor efficacy in checkpoint inhibitor resistant/relapsed models while mitigating liver toxicity risk, computational analysis adds support to dosing strategy -ATG-017, an ERK1/2 inhibitor, in vivo combination supports c...

2021-11-15 08:25 2163

Research into gut microbiome-autism link reveals new perspective in collaborative Austism CRC study

BRISBANE, Australia, Nov. 12, 2021 /PRNewswire/ -- Results published in Cell, led by Mater Research and TheUniversity of Queensland, show that dietary restriction drives microbiome diversity changes in autistic individuals. In the largest study in the field to date, researchers analysed s...

2021-11-12 11:15 1694

Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03

* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abnormal vital signs/laboratory testing results with clinical significance * 20μg ReCOV induced high titer of anti-SARS-CoV-2 neutralizing antibodies, with at least comparable level than published da...

2021-11-12 07:55 2766

Jubilant Biosys Limited Announces New Chemistry Innovation Research Center to Support Expanded Discovery Chemistry and in-vitro ADME Services for Clients like Turning Point Therapeutics

SAN DIEGO and BENGALURU, India, Nov. 11, 2021 /PRNewswire/ -- Jubilant Biosys Limited announced today, an expansion of its facilities to support its discovery chemistry andin-vitro ADME Service offerings. Jubilant Biosys provides services for Turning Point Therapeutics Inc. for multiple small mo...

2021-11-11 21:33 2130

New EZZ genomic products attract strong Chinese interest at CIIE 2021

SYDNEY, Nov. 11, 2021 /PRNewswire/ -- From November 5 to 10, the 4th China International ImportExpo took place in Shanghai, with a focus on global high-tech companies. EZZ Life Science Holdings Limited (ASX: EZZ), a leading company in life sciences inAustralia, was invited to participate for the ...

2021-11-11 04:00 2042

Hill's Pet Nutrition Partners With Bond Pet Foods, Inc. To Develop A Craft Meat Protein Produced Through Precision Fermentation

New Agreement to Explore Sustainable Meat Protein to Provide Long-Term Options for Cat and Dog Nutrition TOPEKA, Kan. and BOULDER, Colo., Nov. 10, 2021 /PRNewswire/ -- Hill's Pet Nutrition, a global leader in biology-based pet nutrition, and Bond Pet Foods, Inc., the Boulder-based leader in crea...

2021-11-10 22:00 1778

Say Cheese: Sophie's BioNutrients co-creates with Ingredion to develop its first microalgae-based dairy-free cheese

SINGAPORE, Nov. 10, 2021 /PRNewswire/ -- Sophie's BioNutrients , a next-generation sustainable urban food production technology company, together withIngredion Idea Labs ® i...

2021-11-10 10:00 2188

One BioMed launches the cartridge-based Xceler8(TM) Nucleic Acid Extraction Platform, the next generation in workflow simplification

SINGAPORE, Nov. 10, 2021 /PRNewswire/ -- One BioMed, a company focused on advancing human health through innovation, announced today the launch of their Xceler8™ Platform for high-yield extraction and purification of nucleic acids from biological samples. Pre-filled with all the necessary reagent...

2021-11-10 08:00 1379

INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.

FDA Lifts Partial Clinical Hold on INNOVATE Phase 3 Segment PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-a...

2021-11-09 21:00 1939

Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative

MANASSAS, Va., Nov. 9, 2021 /PRNewswire/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine wastewater-based epidemiology centers of excellence, as part of theApril...

2021-11-09 20:55 1867

Regrowing Damaged Body Parts: How Osteopore, an Australian-listed Company, is Making it Accessible

SINGAPORE, Nov. 9, 2021 /PRNewswire/ -- Osteopore, an Australian and Singapore based leader in regenerative implants on a commercial scale, is developing technology that enables widespread adoption of tissue engineering. Despite the global average life expectancy rising by more than 6 years betwe...

2021-11-09 18:05 1369

Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting

SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-11-09 16:30 2289

RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill

TEL AVIV, Israel and RALEIGH, NC, Nov. 8, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a strategic agreement with Kukbo Co. Lt...

2021-11-08 20:00 2129

Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases

HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) and Suzhou Alphamab Co., Ltd. (Suzhou Alphamab) jointly announce today that Ascletis' subsidiary and Suzhou Alphamab have entered into an exclusive and worldwide license agreement ou...

2021-11-08 08:30 2433

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...

2021-11-08 08:15 2334
1 ... 949596979899100 ... 168

Week's Top Stories